Physician profile
Thomas M Doolin
NPI 1043347784
$5,694.21
in general payments reported to CMS, 2019-2025
8 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $232 · 2022: $534 · 2023: $1,629 · 2024: $1,707 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,928.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,267.80 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $680.35 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $620.49 | 2023-2024 | Arexvy |
| Lilly USA, LLC | $464.79 | 2023-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $372.34 | 2023-2025 | |
| Novo Nordisk INC | $243.75 | 2021-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.90 | 2024 | Jardiance |
| Pfizer INC. | $18.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Doolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.